ANEUVO
ANEUVO is a Los Angeles-based medical technology company developing the ExaStim Stimulation System, a non-invasive transcutaneous spinal cord stimulation device for patients with paralysis due to incomplete spinal cord injury, approved for clinic and home use.
- Company typePrivate
- Founded2016
- HeadquartersLos Angeles, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ANEUVO does
ANEUVO (legally Niche Biomedical, Inc.) is a Los Angeles-based medical technology company founded in 2016 that develops the ExaStim Stimulation System, a non-invasive transcutaneous spinal cord stimulation device. The system is FDA 510(k)-cleared (April 2026) and CE Mark-certified (April 2025), indicated for patients aged 18 to 75 with paralysis due to incomplete spinal cord injury to improve hand sensation and strength when used in conjunction with functional task practice. The product is approved for both clinic-based and home-based use, and its clinical efficacy is supported by the completed nationwide ASPIRE double-blind trial. The company also holds FDA Breakthrough Device Designation, providing an expedited regulatory pathway for the device.
ANEUVO monetizes primarily through hardware sales of the ExaStim device, with a supplementary professional services revenue stream covering device deployment, clinician training, and ongoing clinical support. Its go-to-market is sales-led enterprise field motion: direct sales to US healthcare facilities and home-use patients, paired with channel/reseller distribution in the European market following CE Mark certification. The addressable customer base is concentrated in the narrow therapeutic niche of incomplete spinal cord injury rehabilitation, and the company currently operates in only two geographies (US and EU).
The company is privately held and venture-backed. It closed a $22 million Series C funding round in March 2026 led by Taiwan-based Catcher Technology Co., Ltd., with proceeds earmarked for scaling manufacturing and quality systems, executing commercial launches in approved markets, and advancing US regulatory activities. Prior funding includes multiple National Science Foundation grants (2016, 2020, 2021) and undisclosed earlier rounds. ANEUVO was also recognized as a winner of Taiwan's 22nd National Innovation Award in the International Startup Award track in February 2026. Headcount is reported in the 11-50 range, consistent with a small, focused commercial-stage organization.
ANEUVO firmographics
Firmographics- Name
- ANEUVO
- Legal name
- Niche Biomedical, Inc.
- Website
- https://aneuvo.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ANEUVO is a Los Angeles-based medical technology company developing the ExaStim Stimulation System, a non-invasive transcutaneous spinal cord stimulation device for patients with paralysis due to incomplete spinal cord injury, approved for clinic and home use.
- Ownership category
- akta.pro rank
ANEUVO industry classification
Industry- Product category
- Neuromodulation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Home Health Care Services (62161)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)
- akta.pro secondary industries
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK), Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC)
Keywords
Where ANEUVO is headquartered
LocationHeadquarters
- HQ city
- Los Angeles
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
ANEUVO business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales
Revenue model
- ExaStim Device Sales: Sale of neuromodulation medical devices (ExaStim Stimulation System) for spinal cord injury rehabilitation, targeting both clinic and home use settings.
- Professional Services: Support services associated with device deployment, training, and ongoing clinical support for the ExaStim system in approved markets.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
ANEUVO product offering
Product offeringCore offering
ANEUVO develops and sells the ExaStim Stimulation System, a non-invasive transcutaneous spinal cord stimulation device for patients aged 18 to 75 with paralysis due to incomplete spinal cord injury. The system is FDA 510(k) cleared and CE Mark certified, approved for both clinical and home use, and is indicated to improve hand sensation and strength when used in conjunction with functional task practice.
Product overview
ANEUVO is a medical technology company with a focused single-product portfolio centered on the ExaStim Stimulation System. The company operates as Niche Biomedical, Inc. d.b.a. ANEUVO, headquartered in Los Angeles. The ExaStim system is the core and only named product, representing a non-invasive neuromodulation device for spinal cord injury rehabilitation.
Differentiator
Problem solved
Functional benefit
Brands
- ExaStim: ExaStim Stimulation System - a non-invasive transcutaneous spinal cord stimulation device for patients with paralysis due to incomplete spinal cord injury.
Products and services
- ExaStim Stimulation System Non-invasive transcutaneous spinal cord stimulation device indicated to improve hand sensation and strength in patients aged 18 to 75 with paralysis due to incomplete spinal cord injury when used in conjunction with functional task practice. Approved for both clinic and home use; FDA 510(k) cleared (April 2026), CE Mark certified (April 2025), and granted FDA Breakthrough Device Designation.
Quantifiable outcome
- Improves hand sensation and strength in patients with incomplete spinal cord injury when used with functional task practice
Companies that use ANEUVO
Customer profileSegments1 record
Ideal customer profiles2 records
ANEUVO technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
ANEUVO partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights6 records
ANEUVO competitors and assessment
Company assessmentDirect peers
- Onward Medical: Onward Medical develops non-invasive and implantable spinal cord stimulation therapies for spinal cord injury recovery, directly competing with ANEUVO's ExaStim in the same SCI rehabilitation use case. Both target restoration of hand and upper-limb function post-injury.
- SpineX: SpineX is developing non-invasive transcutaneous spinal cord stimulation for neurological conditions including spinal cord injury and cerebral palsy. It mirrors ANEUVO's non-invasive neuromodulation approach for SCI rehabilitation.
- Nevro Corp. Nevro is a commercial-stage spinal cord stimulation company focused on chronic pain. It is a direct neuromodulation peer in spinal cord stimulation technology, though it addresses a different indication than ANEUVO's SCI-focused ExaStim.
- Saluda Medical: Saluda Medical develops closed-loop spinal cord stimulation systems for chronic pain and is pursuing adjacent neurological indications. It competes in the same neuromodulation category with a similar evidence-driven, technology-led positioning.
- Axonics Modulation Technologies: Axonics is a commercial neuromodulation company specializing in sacral and tibial stimulation devices. It is a direct peer in the neuromodulation category and shares the small-to-mid-cap medical device commercial profile of ANEUVO.
Broad incumbents
- Boston Scientific: Boston Scientific operates a broad neuromodulation portfolio including spinal cord stimulation, deep brain stimulation, and vagus nerve stimulation. As a major incumbent, it competes with ANEUVO in the spinal cord stimulation category across multiple indications.
- Medtronic: Medtronic is a global medical device leader with a substantial neuromodulation business spanning SCS, DBS, and VNS therapies. It is a broad incumbent in the same neuromodulation technology category as ANEUVO.
- Abbott: Abbott offers a portfolio of neuromodulation devices including spinal cord stimulation systems (e.g., Proclaim) and dorsal root ganglion stimulation. It competes broadly with ANEUVO in neurostimulation technology and clinical applications.
Emerging players
- Helius Medical Technologies: Helius develops non-invasive neuromodulation (Portable Neuromodulation Stimulator/PoNS) for traumatic brain injury-related balance and gait deficits. It shares ANEUVO's non-invasive neurostimulation approach for neurologic rehabilitation, though targeting a different indication.
- Checkpoint Surgical: Checkpoint Surgical develops neurostimulation devices used to locate, evaluate, and protect nerves during surgery. It is an emerging player in the broader neurostimulation category with partial overlap to ANEUVO's neuromodulation focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
ANEUVO social profiles
Digital presenceANEUVO compliance and trust
Trust signalCompliance3 records
ANEUVO financial estimates
Financial estimateRevenue estimate
Valuation estimate
ANEUVO leadership team
Management profileNumber of profiles
ANEUVO funding detail
Funding detailFunding overview
Funding rounds6 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ANEUVO M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ANEUVO
What does ANEUVO do?
ANEUVO develops and sells the ExaStim Stimulation System, a non-invasive transcutaneous spinal cord stimulation device for patients aged 18 to 75 with paralysis due to incomplete spinal cord injury. The system is FDA 510(k) cleared and CE Mark certified, approved for both clinical and home use, and is indicated to improve hand sensation and strength when used in conjunction with functional task practice.
Is ANEUVO a public or private company?
ANEUVO is a private company. It is classified as venture growth investor backed and is currently operating.
When was ANEUVO founded?
ANEUVO was founded in 2016. It employs 11 to 50 people.
Where is ANEUVO based?
ANEUVO is headquartered in Los Angeles, United States, in the North America region.
How does ANEUVO make money?
Two revenue lines are on record. ExaStim Device Sales are the primary driver. The others are professional Services.
Who are ANEUVO's main competitors?
Direct peers on record are Onward Medical, SpineX, Nevro Corp., Saluda Medical and Axonics Modulation Technologies. Broad incumbents are Boston Scientific, Medtronic and Abbott. Emerging players are Helius Medical Technologies and Checkpoint Surgical.
Does ANEUVO have an API?
No public API is recorded for ANEUVO.
What industry is ANEUVO in?
ANEUVO's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAMAG, Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices), with a secondary code of HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 334510 and its SIC code is 3845.